The MA3RS Study Investigators. Circulation 2017;136:787-97. Conclusions: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging is a novel approach to the identification of aortic wall cellular inflammation in patients with abdominal aortic aneurysms, and predicts the rate of aneurysm growth and clinical outcome. However, it does not provide an independent prediction of aneurysm expansion or clinical outcomes in a model incorporating known clinical risk factors.
Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA. PLoS ONE 2017; 12:e0175283. Conclusions: Aspirin use in patients with peripheral vascular disease (PVD) might not be associated with improved cardiovascular outcomes or worse bleeding outcomes. Larger randomized trials assessing the efficacy and safety of aspirin in the contemporary era are mandatory to confirm the current findings. Guideline recommendations regarding the use of aspirin among patients with PVD need to be updated.
Summary: An electronic search of databases was conducted from inception until January 2017 for all randomized trials comparing aspirin with either placebo or control (no aspirin) in patients with PVD. The primary efficacy outcome was all-cause mortality, and the primary safety outcome was major bleeding. Other outcomes of interest were major adverse cardiac and cerebrovascular events, myocardial infarction, stroke, and intracranial hemorrhage. Random-effects summary risk ratios (RRs) were calculated using the Der-Simonian and Liard model. The quality of evidence was assessed by GRADE tool and Cochrane risk of bias assessment tool. A total of 6560 patients (3290 in the aspirin group vs 3270 in the control arm) from 11 trials were included. The mean age was 62 year, 60% were female, 67% designated smokers, and 32% were diabetic. Only two trials were considered to have a low risk of bias, one representing about 50% of the patients included in this metaanalysis.
1 Compared with control, aspirin was associated with a similar incidence of all-cause mortality (8.5% vs 7.7%; RR, 0.93; 95% confidence interval [CI] , 0.8-1.1) and this remained so when limited explicitly to patients without a prior history of ischemic events as well as other pertinent subgroup analysis. When evaluating for major adverse cardiac and cerebrovascular events (RR, 1.0; 95% CI, 0.83-1.20), myocardial infarction (RR, 0.91; 95% CI, 0.67-1.23), and stroke (RR, 0.72; 95% CI, 0.43-1.22) there was no statistical difference found. Comparing aspirin versus control for the primary safety outcome of major bleeding (1.3% vs 1.1%; RR, 1.59; 95% CI, 0.96-2.62), there was no statistical difference with a similar finding for intracranial hemorrhage (RR, 1.38; 95% CI, 0.59-3.21).
Comments: Reevaluating "standard care" is always appropriate because new findings might suggest a need to modify such recommendations. This study has limitations, most notably in not being able to control for other ongoing treatments like statins and antihypertensive agents, all of which could mask the effects of aspirin alone. In addition, the majority of patients are from one randomized, controlled trial.
1 This author believes that this study does support the concept that, in asymptomatic patients with PVD, aspirin provides little cardiovascular event protection. Whether aspirin decreases cardiovascular risk in symptomatic patients with PVS remains controversial, but this study suggests a lack of effective in such patients as well. 
Conclusions:
The findings of this study suggests a potential role for metformin in limiting abdominal aortic aneurysm (AAA) growth.
Summary: The aim of this study was to examine the association of diabetes treatments, particularly metformin, with AAA growth inhibition. AAA growth studied using ultrasound surveillance constituted the patients included in cohort 1, repeated computed tomography for those in cohort 2, and more a detailed repeat computed tomography (including AAA volume) for those in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. In cohort 1, there were 1357 patients with a mean initial AAA diameter of 36.9 mm who were followed for a mean of 4.9 scans and for 3.6 years. The mean annual AAA growth rate was significantly slower (P ¼ .012) in the 118 diabetic patients prescribed metformin (1.03 mm) but not in the 99 diabetic patients not prescribed metformin (1.60 mm) when compared with the 1140 nondiabetics patients not receiving metformin (1.62 mm). A cohort of 2287 patients with a mean initial aortic diameter of 40.9 mm was followed with a mean of 2.9 scans and for 2.9 years. Mean annual AAA growth was significantly slower (P ¼ .004) in the 39 diabetic patients prescribed metformin (1.40 mm), but not in the 30 diabetic patients not prescribed metformin (2.18 mm), than in the 218 nondiabetic patients not receiving metformin (2.55 mm). In cohort 3, the mean annual AAA growth was significantly slower (P ¼ .018) in the 16 diabetic patients prescribed metformin (0.37 mm), but not in the 3 diabetic patients not prescribed metformin (0.95 mm), than in the 34 nondiabetic patients not receiving metformin (1.46 mm). Adjusting for other risk factors did not change these findings in any cohort. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1, adjusted odds ratio [OR] Conclusions: Approximately 50% of patients after aortoenteric fistula (AEF) repair died within 60 days with gastrointestinal complications, increasing the risk of mortality by more than three-fold and representing a surgically modifiable risk factor.
Summary: AEF represent a lethal subset of aortic graft infections and the optimal management remains unclear. The aim of this single-center, retrospective review of consecutive AEF repairs is to identify predictors of morbidity and mortality. Demographics, comorbidities, and perioperative variables were obtained from prospectively collected data, chart review, and the Social Security Death Index. Descriptive statistics, the c 2 test, Kruskal-Wallis test, and Cox proportional hazards modeling were appropriately used based on available data. Between June 1995 and October 2014, 50 patients (30 male; 60%) presented with AEF, with a median age of 70 years (interquartile range, 61-75). The median follow-up for the entire cohort was 14 months (interquartile range, 5-27). Thirty-four subjects (68%) underwent aortic replacement with femoral vein; 12 (24%) with an extraanatomic bypass and aortic ligation, 3 (6%) with a rifampin-soaked Dacron graft, and 1 (2%) with a cryopreserved aortic allograft. The duodenum was the most common location of the enteric defect (n ¼ 40; 80%). Duodenal leak complicated six the primary enteric repairs (12%; two-layered primary repair with/without omental flap), but none of the complex enteric repairs performed with resection and/or bypass. Twenty-three patients (46%) died by 60 days with a higher mortality in those with versus without a gastrointestinal complication (77% vs 35%, respectively; P ¼ .02) and of these was greater in those with a gastrointestinal leak (83%) versus mesenteric ischemia (57%). Advanced age, chronic renal insufficiency, any complications, and gastrointestinal complications (n ¼ 13; 26%) were all associated with an increase in the overall mortality rate on univariate analysis (P < .05). Gastrointestinal complications (hazard ratio, 3.23; 95% confidence interval, 1.27-8.25; P ¼ .015) and advanced age (hazard ratio, 1.07; 95% confidence interval, 1.01-1.13; P ¼ .01) were the only independent predictors of mortality on multivariable regression models.
Comments: The decision to perform a complex versus simple repair of the bowel opening is determined by the patient's condition and overall stability, in addition to the condition of the bowel. But just knowing that failure of the bowel repair is deadly for the patient triggers a heightened awareness and adherence to technical details. As discussed by these authors, the adherence to sound surgical principles with adequate debridement, tension-free repair, and ensuring a viable bowel wall may be more important ultimately than the type of bowel repair.
Bacterial Profile in Human Atherosclerotic Plaques
Lindskog Jonsson A, Hållenius FF, Akrami R, Johansson E, Wester P, Arnerlov C, et al. Atherosclerosis 2017; 263:177-83. Conclusions: There were no major differences in bacterial DNA amount or microbial composition between carotid plaques from asymptomatic and symptomatic patients or between different plaque regions, suggesting that other factors are more important in determining plaque vulnerability.
Summary: Several studies have confirmed the presence of bacterial DNA in atherosclerotic plaques, but its contribution to plaque stability and vulnerability is unclear. In this study, the bacterial plaque profile is investigated to determine if there was a difference between patients who were asymptomatic versus symptomatic and whether there were local differences in the microbial composition within the plaque. Plaques removed by carotid endarterectomy from asymptomatic (n ¼ 11) and symptomatic patients (n ¼ 22) were divided into three different regions known to show different histologic vulnerability: (A) upstream of the maximum stenosis, (B) site for maximum stenosis, and (C) downstream of the maximum stenosis. Bacterial DNA composition in the plaques was determined by performing 454 pyrosequencing of the 16S ribosomal RNA genes, and total bacterial load by quantitative polymerase chain reaction. The sections taken at maximum stenosis were significantly more often of a histologically vulnerable phenotype (82% of 33 sections) compared with upstream (18% of 33 sections) and downstream sections (53% of 30 sections; P < .05). The presence of bacterial DNA was confirmed in the atherosclerotic plaque by quantitative polymerase chain reaction analysis of the 16S ribosomal RNA gene. There was no observed difference (P ¼ NS) in the amount between asymptomatic and symptomatic patients or different plaque regions A, B, and C. Unweighted UniFrac distance metric analysis revealed no distinct clustering of samples by patient group or plaque region. Qualitative filtered sequences were clustered into operational taxonomic units from five different phyla with the majority of the operational taxonomic units belonging to Proteobacteria (48.3%) and Actinobacteria (40.2%). There was no difference between asymptomatic and symptomatic patients, or plaque regions, when analyzing the origin of DNA at phylum, family, or operational taxonomic unit level (P ¼ NS).
Comments: Atherosclerosis is a systemic inflammatory process that might be connected to bacterial infection of local vascular cells, or at a distant site, that then upregulates an immune response. Owing to small patient numbers in this study, there is a risk of a type 2 error hiding a true microbial role in atherosclerosis; however, based on most current data, a direct correlation with a particular bacterial pathogen or family of pathogens seems unlikely. 
Results of the

Conclusions:
The fenestrated ANACONDA stent-graft system offers acceptable technical success rates, midterm efficacy, and durability with respect to aneurysm sac regression, target vessel patency, overall mortality, and reintervention rates. The rate of graft limb occlusion is of concern, especially in case of particularly complex aortic anatomies.
Summary: The fenestrated ANACONDA endograft (Vascutek, Inchinnan, UK) was introduced with the potential advantages of complete repositioning and lack of stent material on the main aortic body to allow more versatility. Because few data are available on its performance, the objective of this study was to assess its midterm results in the treatment of complex aortic aneurysms. This retrospective multicenter observational study gleaned from prospectively collected data includes 86 consecutive patients from >16 centers (82 men; mean age, 73.4 6 8.1 years; 16 [18.6%] symptomatic aneurysms) treated with the custom-made fenestrated ANACONDA endograft from December 2010 to October 2015. The primary endpoint was mortality. Secondary endpoints were technical success in the short term and long term, and morbidity. Two hundred ninety-two visceral/renal vessels were reconstructed with a mean number of 3.4 6 0.6 target vessels per patient with successful reconstruction in 99.3% of the cases (290/292 vessels). Dividing the patients into those without (group 1) versus those with extension to the celiac trunk (group 2, complex), the latter group had excessive neck angulation (4.4% vs 14.6%; P ¼ .002), and required a longer operative time (average, 87 minutes; P ¼ .0001) but similar rates of graft repositioning (w79%). Perioperative technical success was achieved in 86.0% (74/86 patients); this rate was significantly lower in more complex aneurysms with 95.6% in group 1 [43/45 patients] versus 80.5% in group 2 (33/41 patients; P ¼ .03). In-hospital and 30-day mortality rates were 3.5% (three patients) and 7.0% (six patients), respectively. Kaplan-Meier analysis was used for pertinent long-range outcomes with log-rank comparisons. Unless contraindicated, computed tomography angiography was obtained at 1, 6, and 12 months, and then yearly. At 12 and 24 months, the estimated overall survival rate was 88.3% and 85.2%, the target vessel patency rate was 97.2% and 96.3%, and the freedom from aneurysmrelated reintervention rate was 96.3% and 88.0%, respectively. No aneurysm rupture or graft migration was noted at 24 months. At 24 months,
